LifeVantage Co. (NASDAQ:LFVN) Short Interest Update

LifeVantage Co. (NASDAQ:LFVN) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 191,800 shares, a decline of 5.4% from the December 15th total of 202,800 shares. Based on an average daily trading volume, of 110,600 shares, the days-to-cover ratio is presently 1.7 days. Approximately 1.9% of the shares of the stock are short sold.

LifeVantage Price Performance

LFVN opened at $25.31 on Friday. The business has a 50-day moving average of $16.74 and a 200-day moving average of $12.12. LifeVantage has a fifty-two week low of $5.22 and a fifty-two week high of $27.38. The company has a market capitalization of $316.88 million, a PE ratio of 79.10 and a beta of 0.82.

LifeVantage (NASDAQ:LFVN) last posted its earnings results on Tuesday, October 29th. The company reported $0.15 EPS for the quarter, hitting the consensus estimate of $0.15. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%. The firm had revenue of $47.21 million for the quarter.

LifeVantage Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were paid a $0.04 dividend. The ex-dividend date was Monday, December 2nd. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.63%. LifeVantage’s payout ratio is presently 50.00%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on LFVN shares. Lake Street Capital initiated coverage on LifeVantage in a report on Thursday, December 19th. They set a “buy” rating and a $26.00 target price for the company. Craig Hallum began coverage on shares of LifeVantage in a report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 target price for the company.

Hedge Funds Weigh In On LifeVantage

Several large investors have recently made changes to their positions in LFVN. Ritholtz Wealth Management boosted its holdings in LifeVantage by 62.0% in the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock valued at $346,000 after purchasing an additional 10,974 shares during the period. Barclays PLC lifted its stake in shares of LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after buying an additional 11,608 shares during the period. HighTower Advisors LLC acquired a new stake in LifeVantage during the third quarter worth about $638,000. Capital Management Corp VA bought a new position in LifeVantage during the third quarter valued at about $5,073,000. Finally, Renaissance Technologies LLC raised its holdings in LifeVantage by 2.1% in the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after acquiring an additional 17,300 shares in the last quarter. Institutional investors and hedge funds own 35.32% of the company’s stock.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.